Figure 2 | Scientific Reports

Figure 2

From: CD98 heavy chain protein is overexpressed in non-small cell lung cancer and is a potential target for CAR T-cell therapy

Figure 2

Successful development of CAR T cells derived not from H2A011, but from another anti-CD98hc mAb, R8H283, that lacks reactivity with CD98hc glycoforms expressed on normal hematopoietic cells. (A), Constructs for the CAR derived from H2A011. (B), Flow cytometry analysis of H2A011 CAR transduction efficiencies 7 d after CAR transduction. (C, D), Flow cytometric analysis of R8H283 or H2A011 reactivity against phytohemagglutinin P (PHA)-activated T cells (C) and CD3/CD28-stimulated T cells (D). A549 cells were simultaneously stained as a positive control. (E), Flow cytometry analysis of the binding of H2A011 or R8H283 to wild-type (WT) or GnTI-deficient (GnTI−) 293 cells. F, Construct for the CAR derived from R8H283. (G), Growth of R8H283 CAR T cells during in vitro culture. The data are presented as means ± standard error of the mean (SEM). *: p < 0.05. (H), Representative flow cytometry analysis data of R8H283 CAR transduction efficiencies and CD4/CD8 expression in CAR T cells 7 d after CAR transduction.

Back to article page